Prof Old Landgren speaks to ecancer at the 2019 ASH meeting in Orlando about weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) in newly diagnosed multiple myeloma (NDMM).

He reports that the study achieved over 80% MRD negativity in patients treated weekly with wKRd-D in the absence of a bone marrow transplantation.

Prof Landgren discusses the next steps and potential impact of what he describes as the unprecedented results of the study.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.